As my colleague recently mentioned, new doesn’t always mean better. That became true last week for anyone waiting for a new offer from Roche to acquire Genentech. Roche announced its new plan to buy the company last Friday: Roche will approach Genentech’s shareholders directly with an offer of $86.50 per share or $42 billion. Read more »
Key results from a colon cancer study of Genentech’s Avastin (bevacizumab) could be available in April, according to a Securities and Exchange Commission filing. Genentech previously said results would be available mid-year. The drug is currently approved to treat breast and lung cancer, and it’s a first- and second-line treatment for metastatic colorectal cancer. Read more »
The past several months have seen many successful merger and acquisition announcements come and go, but for some companies, this has hardly been a summer of love. Several of Big Pharma’s big offers have been rejected, and some of these stories are still playing out. Only time will tell what the future holds for these proposed deals and sometimes troubled partnerships. Read more »
From PharmTech.com